Advertisement
Canada markets open in 1 hour 41 minutes
  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CAD/USD

    0.7266
    +0.0002 (+0.03%)
     
  • CRUDE OIL

    82.17
    -0.56 (-0.68%)
     
  • Bitcoin CAD

    89,882.73
    +3,665.80 (+4.25%)
     
  • CMC Crypto 200

    1,335.97
    +23.35 (+1.81%)
     
  • GOLD FUTURES

    2,393.70
    -4.30 (-0.18%)
     
  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     
  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     
  • NASDAQ futures

    17,487.25
    -60.00 (-0.34%)
     
  • VOLATILITY

    18.83
    +0.83 (+4.61%)
     
  • FTSE

    7,832.80
    -44.25 (-0.56%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6817
    -0.0004 (-0.06%)
     

Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and MyoKardia

NEW YORK, NY / ACCESSWIRE / July 3, 2018 / U.S. equities closed up on Monday, supported by a rally from the technology sector. However, growing trade concerns continue to weigh on the markets. The Dow Jones Industrial Average increased 0.15 percent to close at 24,307.18, while the S&P 500 Index jumped 0.31 percent to close at 2,726.71. The Nasdaq Composite Index climbed 0.76 percent to close at 7,567.69.

"When Trump starts talking about the WTO, China, all these big economies and these big threats, the market is going to react to that. It creates turmoil, and people are getting frustrated with all the back and forth. I think the long-term growth story of the economy remains intact, but in the meantime the trade will can cause a lot of tremors in the short term," said Mark Esposito, president of Esposito Securities, a Dallas-based asset manager.

RDI Initiates Coverage on:

Intercept Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=ICPT

ADVERTISEMENT

MyoKardia, Inc.
https://rdinvesting.com/news/?ticker=MYOK

Intercept Pharmaceuticals' stock jumped 5.71% Monday, to close the day at $88.70. The stock recorded a trading volume of 590,811 shares, which was below its three months average volume of 764,915 shares. In the last year, Intercept Pharmaceuticals' shares have traded in a range of 51.05 - 135.59. The share price has gained 73.75% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $76.48 is above its 200-day moving average of $66.52. Shares of Intercept Pharmaceuticals have gained roughly 19.38 percent in the past month and are up 51.83 percent year-to-date.

Access RDI's Intercept Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ICPT

On Monday, shares of MyoKardia recorded a trading volume of 646,306 shares, which was above the three months average volume of 401,435 shares. The stock ended the day 5.24% higher at $52.25. The share price has fallen 16.84% from its 52 week high with a 52 week trading range of 12.85 - 62.83. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $48.31 is below its 200-day moving average of $49.40. Shares of MyoKardia have gained roughly 7.84 percent in the past month and are up 24.11 percent year-to-date.

Access RDI's MyoKardia, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MYOK

Our Actionable Research on Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) and MyoKardia, Inc. (NASDAQ: MYOK) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com